Table 1. The mean percentage of PB CD3+/CD4+/CD28+ and CD3+/CD8+/CD28+ cells before and after 24, 48, 72 and 96 h of anti-CD3+rIL-2 stimulation in patients with B-CLL and healthy controls.

	Time (h)
	0	24	48	72	96	P
CD3+/CD4+/CD28+
B-CLL patients (n=33)	41.5±17.1%	20.1±9.2%	22.1±9.9%	35.7±13.5%	36.2±12.6%	I : III=0.001
	(I)	(III)	(V)	(VII)	(IX)	I : V=0.005
						III : V=NS
						V : VII=0.001
Healthy controls (n=25)	78.9±7.6%	57.0±8.5%	74.7±6.5%	82.2±6.0%	82.1±6.4%	II : IV=0.002
	(II)	(IV)	(VI)	(VIII)	(X)	IV : VI=0.004
						II : VI=NS
						VI : VIII=NS
P	I : II=0.0002	III : IV=0.0001	V : VI=0.0001	VII : VIII=0.0001	IX : X=0.0001
CD3+/CD8+/CD28+
B-CLL patients (n=33)	36.3±17.6%	20.3±12.2%	25.1±18.4%	41.0±15.7%	40.2±11.1%	I : III=0.04
	(I)	(III)	(V)	(VII)	(IX)	I : V=0.05
						III : V=NS
						V : VII=0.02
Healthy controls (n=25)	59.3±9.8%	42.6±11.2%	52.5±8.3%	54.7±8.3%	55.0±7.6%	II : IV=0.04
	(II)	(IV)	(VI)	(VIII)	(X)	IV : VI=0.05
						II : VI=NS
						VI : VIII=NS
P	I : II=0.005	III : IV=0.001	V : VI=0.001	VII : VIII=0.01	IX : X=0.01